While this is right on some level... the incentives aren't the main driver. Finding good targets in biotech is just a harder problem to solve. Like way harder.

While this is right on some level... the incentives aren't the main driver. Finding good targets in biotech is just a harder problem to solve. Like way harder. Disease biology is complex as hell. At the other end, figuring the interplay between one target protein and a potential molecule to act as a therapy is much easier (it's still complex, and there is a little more to it than that, but not anything like finding a good target).